

For lymphoid neoplasms, 504 cases have been diagnosed according to WHO criteria and have documented informed consent. A total of 457 questionnaires have been validated and 394 of these have reached exposure-completed status. Controls have been assigned, informed consent documented and questionnaires validated for at least 456 of these cases, and preliminary exposure assessment completed on controls for approximately 410 cases. The recruitment of lymphoid cases is scheduled to continue through December 31, 2008. However, routine hematology services, accrual of new hematology cases and follow-up activities for DP will end this month.

Table 1. Current Study Cases Diagnosed as of May 31st, 2007.

Classification	Case Accrual (5/31/07)
AML	681
Lymphoid Neoplasms	504
MDS	586
AA	136
BID*	59

*Benzene-induced dysplasia, Irons et al (2006) Leukemia Research 30: 769-775

Follow-up

Patients initially diagnosed in the disease progression study are contacted at 6-month intervals and asked to return for follow-up evaluation. As of the end of May 2007, the laboratory has evaluated a total of 255 follow up cases.

In order to diagnose cases that are relevant to the case control study, other disease outcomes have been accrued as part of DP. These include, but are not limited to, the selected outcomes listed in Table 2.

Table 2. Case Accrual for Other Selected Outcomes.

Additional Outcomes	Case Accrual (5/31/07)
Cytopenias	131
CML	90
Nutritional Deficiencies	294

Quality Assurance/Quality Control

IC/EA documentation

Implementation of procedures to remediate documentation of IC's at the Tumor Hospital have been generally successful. To date, Tumor Hospital staff have contacted a total of 144 cases of lymphoid neoplasms for which IC could not be documented. Informed consents have been signed, questionnaires have been administered and new controls assigned for 65 of these